Tune Therapeutics was founded upon cutting-edge advances in the mechanics of gene regulation. Our ‘genetic tuning’ technology enables exquisite levels of control over gene activity – activating, silencing, and fine-tuning the output of specific genes to …

Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine. Tune is pioneering a new therapeutic modality that can fine-tune any gene network.

With its unique ability to fine-tune cell properties – combined with the power to direct entire cell states, fates, and phenotypes via multiplex editing – genetic tuning opens the door to the rapid development and application of effective, regenerative therapeutics.

Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

Jan 12, 2025 · Genetic medicine startup Tune Therapeutics has raised another $175 million to develop therapies capable of “tuning” genes to treat disease, rather than editing them by cutting or replacing DNA directly.

Jan 13, 2025 · Tune-401 is a first-in-class investigational product candidate for treating Hepatitis B (HBV) infection. Tune-401 utilizes the company’s versatile, modular TEMPO platform to epigenetically silence viral HBV intDNA and cccDNA necessary for sustained HBV infection.

Oct 9, 2023 · Today, we’re looking at Tune Therapeutics, a preclinical biotech pioneering a next-generation genetic therapy by tuning the epigenome. In focus with: Lucas Thompson, senior director of the ex vivo program at Tune Therapeutics.

May 22, 2023 · In a detailed poster presentation, Tune scientists showed that HER2-targeting human CAR T-cells could be epigenetically modified ex vivo to enhance their ability to proliferate, persist, and...

Dec 6, 2023 · For the first time, Tune Therapeutics made data available to support their chronic HBV program, showing that it can safely silence key viral persistence and replication mechanisms in various...

TUNE-401 is a first-in-class investigational product candidate for the treatment of Hepatitis B (HBV) infection. TUNE-401 utilizes Tune’s TEMPO platform to epigenetically silence viral HBV DNA in host chromosomes, while simultaneously silencing the extra-chromosomal, cccDNA “viral factories” necessary for sustained HBV infection.